

## **ASX MEDIA RELEASE**

# **Uscom China Registered**

### Wholly owned foreign subsidiary and office established in Beijing

**SYDNEY, Australia, Monday 12<sup>th</sup> November 2018:** Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) announced the establishment and registration of Uscom China. Uscom China is a wholly owned subsidiary of Uscom Limited, Sydney, Australia, and will be the operational centre for Uscom business in China. The new Uscom China office is located in Beijing's business and technology sector in the Chaoyang district.

The registration of Uscom China is a commitment to the Chinese market, designed to underwrite growth by achieving favoured status as a supplier, and accessing simplified processes for product and IP registrations, product importation, staff employment and administration.

The establishment of Uscom China comes following significant cornerstone Chinese investment in Uscom and the appointment of Beijing based Ms Teresa Guo as Uscom Director of China Operations.

Uscom CEO Associate Professor Rob Phillips said: "Uscom China in Beijing is a critical step forward for our business and further aligns us with the largest and fastest growing medical device market in the world as we steer our 7 new devices through NMPA regulatory (ex CFDA). China and SE Asia were responsible for more than 60% of our global revenues in 2017 with the Chinese economy continuing to grow in excess of 6.5% pa, and we are aggressively targeting growth in this region. Registration of Uscom China allows us to hold our own regulatory certifications, employ staff directly, be a preferred supplier for Government tenders, and directly import all our devices. It will also provide us with direct connection to our market and allow us to expand clinical and technical support to our growing China install base. China is a massive and rapidly growing medical device market and we have great people, great connections, and now the foundations for a great organization in China. This is a very exciting initiative for Uscom."

#### **China Health market:**

- ~1.4B population
- ~2.8M doctors
- ~2.6M nurses
- ~25,000 hospitals (15,000 public, 10,000 private)
- ~1,000,000 primary healthcare facilities
- ~14,000 specialised public health facilities

#### References:

Dr Junhua Zhang, 'Development Strategies of Human Resources for Health in China', Health Human Resources Development Center, the National Health and Family Planning Commission, People's Republic of China, 2014.



## **ASX MEDIA RELEASE**

#### **About Uscom**

**Uscom Limited (UCM)** is an ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

**The USCOM 1A** is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+Reporter, an innovative stand alone software solution that provides a digital platform to archive patient examinations, trend measure progress over time, analyse pulse pressure waves and generate a summary report.

**Uscom SpiroSonic digital ultrasonic spirometers** are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary **SpiroReporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations, trend measure progress over time, analyse spirometry outputs and generate a summary report.

For more information, please visit: www.uscom.com.au

**Uscom Contacts** 

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au